门冬胰岛素30强化治疗2型糖尿病并脑梗塞的临床疗效及安全性评价

Clinical Efficacy and Safety Evaluation of Intensive Insulin Aspart 30 Therapy in Patients with Type 2 Diabetes and Cerebral Infarction

目的探讨门冬胰岛素30(诺和锐30)强化治疗2型糖尿病并脑梗塞的临床疗效及安全性。方法进行为期2周的随机、开放性比较研究,100例患者随机分为治疗组和对照组各50例。两组均采用内科常规治疗,对照组给予诺和灵30R每日早、晚餐前皮下注射方案,治疗组给予诺和锐30每日早、中、晚餐前3次皮下注射强化方案,两组疗程均为14 d。比较两组空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、低血糖事件及神经功能缺损评分(NDS)的差异。结果两组治疗后FBG、2 hPG及神经功能缺损评分均优于治疗前(P<0.05),而且治疗组低血糖发生次数及神经功能缺损评分显著低于对照组(P<0.05)。结论诺和锐30强化治疗2型糖尿病并脑梗塞患者能有效降低血糖,减少低血糖事件,改善神经功能缺损评分,有更好的临床疗效及安全性。

Objective To investigate the efficacy and safety of intensive insulin aspart 30 （ Novomix 30） therapy in patients with type 2 diabetes and cerebral infarction. Methods Two-week randomized, open- label,controlled trial comparing Novolin 30R with intensive Novmix 30 was performed. 100 cases were randomly divided into treatment group and control group, 50 cases of each. The two groups were given traditional medical treatment, while the control group received Novolin 30R twice per day, the treatment group received Novomix 30 thrice per day. the treatment course of two groups was 14 days. the indicators such as FBG,2 hPG, HbA1 c, hypoglycemia incidence and neurological deficit scores（NDS） were evaluated. Results After the treatment, the FBG,2 hPG, HbA1C and NDS of two groups were respectively lower than those before, while the NDS and hypoglycemia incidence of the treatment group was better than those of the control group, and the difference was statistically significant （P 〈 O. 05 ）. Conclusion Intensive insulin aspart 30 therapy can reduce FBG and 2 hPG, and reduce the incidence of low blood sugar, meanwhile improve neurological deficit scores and has a better clinical efficacy and safety in patients with type 2 diabetes and cerebral infarction.